Dr. Reddy's Mode of Discovery

The Indian drugmaker's CEO explains the company's move from generic offerings, and its intent on securing a spot among the world's top 25 pharma companies

Since its founding, Dr. Reddy's Laboratories has predominantly been a generics player, with North America accounting for nearly half its revenue. But in 2005, the Hyderabad (India)-based pharmaceutical manufacturer teamed up with venture capitalists to set up an independent arm for new drug discovery. It's now looking at innovations to drive its ambition of becoming one of the world's top 25 pharma players.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.